Valproic acid oral - Banner Life Sciences

Drug Profile

Valproic acid oral - Banner Life Sciences

Alternative Names: Stavzor; Stavzor ER; Valproic acid delayed-release capsules (Stavzor); Valproic acid extended-release capsules (Stavzor ER)

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Banner Pharmacaps
  • Developer Banner Life Sciences; Banner Pharmacaps
  • Class Antiepileptic drugs; Antimigraines; Nootropics; Small molecules
  • Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Neurotransmitter modulators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Epilepsy; Migraine

Most Recent Events

  • 01 Dec 2016 Banner Pharmacaps is now called Banner Life Sciences
  • 15 Mar 2016 Biomarkers information updated
  • 14 Dec 2012 Banner Pharmacaps has been acquired by Patheon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top